Literature DB >> 22329899

Agmatine attenuates methamphetamine-induced conditioned place preference in rats.

David A Thorn1, Jerrold C Winter, Jun-Xu Li.   

Abstract

The polyamine agmatine modulates a variety of behavioral effects including the abuse-related effects of opioids and has been proposed as a potential medication candidate for the treatment of opioid abuse. However, little is known of the effects of agmatine on the abuse-related effects of other drugs of abuse. This study examined the effects of agmatine on the rewarding effects of methamphetamine in rats using a conditioned place preference paradigm. Methamphetamine (0.1-1.0mg/kg) dose-dependently increased the time spent in methamphetamine-paired side (place preference). Agmatine, at doses that did not produce place preference or aversion (10-32mg/kg), significantly decreased the development of methamphetamine-induced place preference when agmatine was administered in combination with methamphetamine during place conditioning. Agmatine also significantly decreased the expression of methamphetamine-induced place preference when an acute injection of agmatine was given immediately before test session. These doses of agmatine do not alter the motor activity in rats, suggesting that the observed attenuation of methamphetamine-induced place preference was not due to general behavioral disruption. Together, these data suggests that agmatine attenuates the rewarding effects of methamphetamine and may be able to modulate the abuse liability of methamphetamine.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22329899     DOI: 10.1016/j.ejphar.2012.01.037

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Chronic variable stress and intravenous methamphetamine self-administration - Role of individual differences in behavioral and physiological reactivity to novelty.

Authors:  S B Taylor; L R Watterson; P R Kufahl; N E Nemirovsky; S E Tomek; C D Conrad; M F Olive
Journal:  Neuropharmacology       Date:  2016-05-07       Impact factor: 5.250

2.  Agmatine attenuates the discriminative stimulus and hyperthermic effects of methamphetamine in male rats.

Authors:  David A Thorn; Jiuzhou Li; Yanyan Qiu; Jun-Xu Li
Journal:  Behav Pharmacol       Date:  2016-09       Impact factor: 2.293

3.  Effects of the trace amine-associated receptor 1 agonist RO5263397 on abuse-related effects of cocaine in rats.

Authors:  David A Thorn; Li Jing; Yanyan Qiu; Amy M Gancarz-Kausch; Chad M Galuska; David M Dietz; Yanan Zhang; Jun-Xu Li
Journal:  Neuropsychopharmacology       Date:  2014-04-18       Impact factor: 7.853

4.  The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.

Authors:  Andrew C Harris; Mark G LeSage; David Shelley; Jennifer L Perry; Paul R Pentel; S Michael Owens
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

Review 5.  Brain Histamine N-Methyltransferase As a Possible Target of Treatment for Methamphetamine Overdose.

Authors:  Junichi Kitanaka; Nobue Kitanaka; F Scott Hall; George R Uhl; Motohiko Takemura
Journal:  Drug Target Insights       Date:  2016-03-02

Review 6.  Effects of drugs of abuse on hippocampal plasticity and hippocampus-dependent learning and memory: contributions to development and maintenance of addiction.

Authors:  Munir Gunes Kutlu; Thomas J Gould
Journal:  Learn Mem       Date:  2016-09-15       Impact factor: 2.460

7.  Effects of imidazoline agents in a rat conditioned place preference model of addiction.

Authors:  V Şorodoc; G Rusu-Zota; P Nechita; C Moraru; O M Manole
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-01-08       Impact factor: 3.000

8.  Conditioned place preference following concurrent treatment with 3, 4-methylenedioxypyrovalerone (MDPV) and methamphetamine in male and female Sprague-Dawley rats.

Authors:  Harmony I Risca; Julio D Zuarth-Gonzalez; Lisa E Baker
Journal:  Pharmacol Biochem Behav       Date:  2020-09-01       Impact factor: 3.533

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.